LUSSANA, FEDERICO
LUSSANA, FEDERICO
Dipartimento di Oncologia ed Emato-Oncologia
Adapting the Fitness Criteria for Non-Intensive Treatments in Older Patients with Acute Myeloid Leukemia to the Use of Venetoclax-Hypomethylating Agents Combination—Practical Considerations from the Real-Life Experience of the Hematologists of the Rete Ematologica Lombarda
2024 G. Rossi, E. Borlenghi, P. Zappasodi, F. Lussana, M. Bernardi, C. Basilico, A. Molteni, I. Lotesoriere, M. Turrini, M. Frigeni, M. Fumagalli, P. Cozzi, F. Gigli, C. Cattaneo, N.S. Fracchiolla, M. Riva, G. Martini, V. Mancini, R. Cairoli, E. Todisco
Autologous versus allogeneic hematopoietic cell transplantation for older patients with acute lymphoblastic leukemia. An analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
2023 S. Giebel, M. Labopin, M. Houhou, D. Caillot, J. Finke, D. Blaise, N. Fegueux, M. Ethell, J.J. Cornelissen, E. Forcade, I. Yakoub-Agha, F. Lussana, J. Maertens, J.H. Bourhis, P. Jindra, N.C. Gorin, A. Nagler, M. Mohty
Danazol Treatment for Thrombocytopenia in Myelodysplastic Syndromes: Can an "Old-fashioned" Drug be Effective?
2023 M. Riva, A. Bosi, L. Rizzo, F. Mazzon, S. Ferrari, F. Lussana, L. Borin, A. Castelli, R. Cairoli, W. Barcellini, A. Molteni, B. Fattizzo
Optimal Use of Novel Immunotherapeutics in B-Cell Precursor ALL
2023 F. Lussana, G. Cavallaro, P. De Simone, A. Rambaldi
Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL study
2023 D. Ocadlikova, F. Lussana, N. Fracchiolla, M. Bonifacio, L. Santoro, M. Delia, S. Chiaretti, C. Pasciolla, A. Cignetti, F. Forghieri, F. Grimaldi, G. Corradi, L. Zannoni, De , S. Propris, G.M. Borleri, I. Tanasi, J. Vadakekolathu, S. Rutella, A.R. Guarini, R. Foà, A. Curti
Sequential allogeneic transplantation and ruxolitinib maintenance for a synchronous PCM1-JAK2 positive myeloid sarcoma and acute B-lymphoblastic leukemia
2022 G. Rizzuto, M. Leoncin, S. Imbergamo, D. Taurino, M.C. Mico, M. Tosi, A. Michelato, K. Buklijas, O. Spinelli, F. Lussana, F. Lessi, M. Pizzi, L. Bonaldi, G. Binotto, A. Rambaldi, C. Gurrieri
{COVID}-19 infection in acute lymphoblastic leukemia over 15 months of the pandemic. A Campus {ALL} report
2022 S. Chiaretti, M. Bonifacio, R. Agrippino, F. Giglio, M. Annunziata, A. Curti, M. Ilaria Del Principe, P. Salutari, M. Scium(`(e)), M. Delia, M. Armenio, V. Mancini, A. Mul(`(e)), F. Grimaldi, G. Rege-Cambrin, L. Santoro, F. Lussana, P. Chiusolo, C. Pasciolla, A. Maria Scattolin, M. Cerrano, M. Ciccone, M. Defina, F. Forghieri, C.M. Mazzone, M. Piccini, F. Ferrara, G. Pizzolo, R. Fo(`(a))
Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies
2021 S. Ferrari, C. Caprioli, A. Weber, A. Rambaldi, F. Lussana
Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell-Redirected Bispecific Antibodies
2021 F. Lussana, G. Gritti, A. Rambaldi
Concurrent diagnosis of acute myeloid leukemia and symptomatic covid-19 infection: A case report successfully treated with azacitidine-venetoclax combination
2021 D. Taurino, M. Frigeni, A. Grassi, G. Cavallaro, S. Salmoiraghi, O. Spinelli, A. Rambaldi, F. Lussana
Mrd‐based therapeutic decisions in genetically defined subsets of adolescents and young adult philadelphia‐negative all
2021 M. Tosi, O. Spinelli, M. Leoncin, R. Cavagna, C. Pavoni, F. Lussana, T. Intermesoli, L. Frison, G. Perali, F. Carobolante, P. Viero, C. Skert, A. Rambaldi, R. Bassan
Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
2021 M. Bonifacio, C. Papayannidis, F. Lussana, N. Fracchiolla, M. Annunziata, S. Sica, M. Delia, R. Foà, G. Pizzolo, S. Chiaretti
Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell–Redirected Bispecific Antibodies
2021 F. Lussana, G. Gritti, A. Rambaldi
Skip pattern approach toward the early access of innovative anticancer drugs
2021 G. Apolone, A. Ardizzoni, A. Biondi, A. Bortolami, C. Cardone, C.M. Ciniselli, P. Conte, C. Crippa, F. de Braud, M. Duca, S. Gori, G. Gritti, A. Inno, R. Luksch, F. Lussana, M. Maio, G. Pasello, F. Perrone, A. Rambaldi, G. Rossi, D. Signorelli, G. Soverini, M. Valente, P. Verderio, G. Buzzetti
High Throughput Molecular Characterization of Normal Karyotype Acute Myeloid Leukemia in the Context of the Prospective Trial 02/06 of the Northern Italy Leukemia Group (NILG)
2020 S. Salmoiraghi, R. Cavagna, P. Zanghi', C. Pavoni, A. Michelato, K. Buklijas, L. Elidi, T. Intermesoli, F. Lussana, E. Oldani, C. Caprioli, P. Stefanoni, G. Gianfaldoni, E. Audisio, E. Terruzzi, L. De Paoli, E. Borlenghi, I. Cavattoni, D. Mattei, A. Scattolin, M. Tajana, F. Ciceri, E. Todisco, L. Campiotti, P. Corradini, N. Fracchiolla, R. Bassan, A. Rambaldi, O. Spinelli
D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study
2020 G. Palareti, C. Legnani, E. Antonucci, B. Cosmi, D. Poli, S. Testa, A. Tosetto, W. Ageno, A. Falanga, P.M. Ferrini, V. Pengo, P. Prandoni, D. Prisco, A. Ghirarduzzi, M.R. Veropalumbo, M.C. Ugolotti, N. Erba, V. De Micheli, O. Paoletti, S. Luigi, M. Donadini, E. Rancan, R. Quintavalla, R.C. Santoro, F. Orlandini, R. Benedetti, M. Cattaneo, F. Lussana, E. Bertinato, R. Cappelli, A.M. Pizzini, A. D'Angelo, L. Crippa, L. Angeloni, R. Bortolotti, M.R. Vandelli, A. Tripodi, D. Imberti, M. Moia, R. Pesavento, N. Magrini, F. Marongiu, P. Zonzin, N. Piaggesi, M. Silingardi
Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06
2020 C. Caprioli, F. Lussana, S. Salmoiraghi, R. Cavagna, K. Buklijas, L. Elidi, P. Zanghi', A. Michelato, F. Delaini, E. Oldani, T. Intermesoli, A. Grassi, G. Gianfaldoni, F. Mannelli, D. Ferrero, E. Audisio, E. Terruzzi, L. De Paoli, C. Cattaneo, E. Borlenghi, I. Cavattoni, M. Tajana, A.M. Scattolin, D. Mattei, P. Corradini, L. Campiotti, F. Ciceri, M. Bernardi, E. Todisco, A. Cortelezzi, B. Falini, C. Pavoni, R. Bassan, O. Spinelli, A. Rambaldi
National Italian Delphi panel consensus: which measures are indicated to minimize pegylated-asparaginase associated toxicity during treatment of adult acute lymphoblastic leukemia?
2020 F. Lussana, P. Minetto, F. Ferrara, S. Chiaretti, G. Specchia, R. Bassan
Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities
2020 C.F. Magnani, G. Gaipa, F. Lussana, D. Belotti, G. Gritti, S. Napolitano, G. Matera, B. Cabiati, C. Buracchi, G. Borleri, G. Fazio, S. Zaninelli, S. Tettamanti, S. Cesana, V. Colombo, M. Quaroni, G. Cazzaniga, A. Rovelli, E. Biagi, S. Galimberti, A. Calabria, F. Benedicenti, E. Montini, S. Ferrari, M. Introna, A. Balduzzi, M.G. Valsecchi, G. Dastoli, A. Rambaldi, A. Biondi
Evaluation of platelet function in essential thrombocythemia under different analytical conditions
2020 F. Lussana, E.A. Femia, M. Pugliano, G. Podda, C. Razzari, N. Maugeri, A. Lecchi, S. Caberlon, G. Gerli, M. Cattaneo